Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 15/20 | 0.61 |
| ▸ | GABRB3 | P28472 | 15/20 | 0.61 |
| ▸ | GABRA3 | P34903 | 13/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 12/20 | 0.61 |
| ▸ | GABRA2 | P47869 | 10/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 10/20 | 0.61 |
| ▸ | GABRA6 | Q16445 | 8/20 | 0.61 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.61 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2840544 | 0.87 | GABRG2 (0.65) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL2845742 | 0.86 | GABRG2 (0.78) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL14484338 | 0.85 | GABRG2 (0.69) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL14484229 | 0.84 | GABRG2 (0.69) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL2848885 | 0.81 | GABRG2 (0.62) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL3139898 | 0.80 | GABRG2 (0.79) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL14186978 | 0.80 | GABRG2 (0.77) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL14187064 | 0.79 | GABRG2 (0.65) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL2846876 | 0.79 | GABRG2 (0.60) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL17088099 | 0.78 | GABRG2 (0.82) | GABRG2GABRB3GABRA3GABRA5GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | WISYS TECHNOLOGY FOUNDATION (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | GABRA5, GABRA6, GABRA2 | GABRG2 11/4885GABRB3 16/4885GABRA3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.